Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | ACP1 | P24666 | 3/20 | 0.32 |
| ▸ | CDC25B | P30305 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 3/20 | 0.30 |
| ▸ | CES1 | P23141 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13052135 | 1.00 | PRKCA (0.36) | PRKCAPRKCEPOLBFASNPTPN1 | |
| SCHEMBL13052133 | 0.95 | POLB (0.35) | POLBFASNPTPN1ACP1CDC25B | |
| SCHEMBL13052132 | 0.91 | POLB (0.38) | POLBFASNPTPN1ACP1CDC25B | |
| SCHEMBL835135 | 0.85 | CES2 (0.41) | PRKCAPRKCEPTPN1CES2CES1 | |
| SCHEMBL863512 | 0.81 | CES2 (0.45) | PTPN1CES2CES1 | |
| SCHEMBL19628786 | 0.81 | CES2 (0.45) | PTPN1CES2CES1 | |
| SCHEMBL13409098 | 0.76 | PAOX (0.38) | PRKCAPRKCE | |
| SCHEMBL16966580 | 0.73 | GPR84 (0.59) | PTPN1 | |
| SCHEMBL1333129 | 0.73 | GPR84 (0.59) | PTPN1 | |
| SCHEMBL16966579 | 0.73 | GPR84 (0.59) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436042-B2 | Adducts of levulinic derivatives with epoxidized fatty acid esters and uses thereof | SEGETIS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100292373-A1 | ADDUCTS OF LEVULINIC DERIVATIVES WITH EPOXIDIZED FATTY ACID ESTERS AND USES THEREOF | GFBIOCHEMICALS LIMITED (MT) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292373-A1 | ADDUCTS OF LEVULINIC DERIVATIVES WITH EPOXIDIZED FATTY ACID ESTERS AND USES THEREOF | ALOX5, ELOVL5, ELOVL1 | PRKCA 364/4885PRKCE 326/4885POLB 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.